Nasdaq:US$14.95 (-0.50) | HKEX:HK$23.62 (-0.60) | AIM:£2.36 (+0.06)
What We Do

We are an innovative, commercial-stage biopharmaceutical company based in China, striving to create differentiated novel oncology and immunology treatments with potential to be marketed globally.

Over the past 20 years, we have established a fully integrated oncology business, from discovery and development, all the way to manufacturing to commercialization.